Additionally, glucan‐type LBPs have been found to reduce liver inflammation and damage by downregulating the harmful bacteria enterococcus and its metabolite lipopolysaccharide (LPS) in high‐fat diet‐induced NAFLD rats, thereby inhibiting the activation of the LPS/TLR4/NF‐κB signaling pathway (Gao et al. 2021). Here, NFKB1 is linked to metabolic dysfunction-associated steatotic liver disease.